1. Introduction: History of the management of advanced renal cell cancer

   • Janice P. Dutcher

   Editorial 14 January 2009 Pages: 1 - 2

2. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma

   • Antonio Romo de Vivar Chavez
   • Michael E. de Vera
   • Michael T. Lotze

   Original Paper 16 January 2009 Pages: 3 - 12

   

3. The application of high-dose interleukin-2 for metastatic renal cell carcinoma

   • David F. McDermott

   Original Paper 16 January 2009 Pages: 13 - 17

4. Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy

   • Michael B. Atkins

   Original Paper 23 January 2009 Pages: 18 - 22

   

5. IL-2 in the therapy of melanoma and other malignancies

   • Kim Margolin

   Original Paper 28 January 2009 Pages: 23 - 31

6. Mechanism of action of everolimus in renal cell carcinoma

   • Bernard Escudier
   • John A. Thompson

   Original Paper 28 January 2009 Pages: 32 - 39

   

7. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: biology and pathways

   • James M. G. Larkin
   • Rosemary E. J. Clarke
   • Lisa M. Pickering

   Original Paper 14 January 2009 Pages: 40 - 45

8. Everolimus for renal cell carcinoma: predictive factors for response and future directions

   • Guru Sonpavde
   • Thomas E. Hutson

   Original Paper 16 January 2009 Pages: 46 - 53

   

9. RAD-001: future directions

   • Ronald M. Bukowski

   Original Paper 16 January 2009 Pages: 54 - 57